XML 35 R23.htm IDEA: XBRL DOCUMENT v3.26.1
Subsequent Event
6 Months Ended
Jun. 30, 2026
Subsequent Events [Abstract]  
Subsequent Event Subsequent Event
On June 12, 2026, the Company entered into an asset purchase agreement (the "PRV Transfer Agreement") pursuant to which the Company agreed to sell its Rare Pediatric Disease Priority Review Voucher ("PRV") for gross proceeds of $195.0 million in cash. The Company received the PRV in connection with the FDA accelerated approval of AVLAYAH in March 2026. On July 27, 2026, the Company completed the sale and received gross proceeds of $195.0 million pursuant to the terms of the PRV Transfer Agreement. No proceeds or gain from the sale were recognized in the condensed consolidated financial statements as of and for the three and six months ended June 30, 2026.